Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | BlackRock Inc. BLK | 1,974,452 5.300% | 1,974,452 (New Position) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,049,572 8.200% | 39,899 (+1.33%) | Filing History |
| 2024-06-26 4:54 pm Purchase | 2024-06-24 | 13D | Entrada Therapeutics, Inc. TRDA | BAKER BROS. ADVISORS LP | 4,865,819 13.200% | 161,400 (+3.43%) | Filing History |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group LLC | 1,283,735 3.800% | -570,373 (-30.76%) | Filing History |
| 2024-02-14 4:12 pm Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | ROCHE FINANCE LTD | 2,744,120 8.200% | -69,405 (-2.47%) | Filing History |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,009,673 9.000% | -4,704 (-0.16%) | Filing History |
| 2023-02-14 4:25 pm Sale | 2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group LLC | 1,854,108 5.900% | -100,312 (-5.13%) | Filing History |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,014,377 9.600% | 993,740 (+49.18%) | Filing History |
| 2023-02-06 2:51 pm Sale | 2022-12-30 | 13G | Entrada Therapeutics, Inc. TRDA | Wellington Management Group LLP | 1,010,351 3.220% | -2,103,655 (-67.55%) | Filing History |
| 2022-02-14 5:07 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Redmile Group LLC | 1,954,420 6.300% | 1,954,420 (New Position) | Filing History |
| 2022-02-14 2:35 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 2,020,637 6.400% | 2,020,637 (New Position) | Filing History |
| 2022-02-14 06:19 am Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | ROCHE FINANCE LTD | 2,813,525 9.000% | 2,813,525 (New Position) | Filing History |
| 2022-02-08 12:03 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | MRL Ventures Fund LLC | 1,739,768 5.600% | 1,739,768 (New Position) | Filing History |
| 2022-02-04 09:17 am Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | Wellington Management Group LLP | 3,114,006 9.980% | 3,114,006 (New Position) | Filing History |
| 2021-12-16 5:23 pm Unchanged | 2021-12-14 | 13D | Entrada Therapeutics, Inc. TRDA | BAKER BROS. ADVISORS LP | 4,704,419 15.100% | 0 (Unchanged) | Filing History |
| 2021-11-12 4:30 pm Purchase | 2021-11-02 | 13D | Entrada Therapeutics, Inc. TRDA | 5AM Ventures V L.P. | 4,409,687 14.800% | 4,409,687 (New Position) | Filing History |
| 2021-11-12 4:07 pm Purchase | 2021-11-02 | 13D | Entrada Therapeutics, Inc. TRDA | MPM BioVentures 2014, L.P. | 4,427,092 14.800% | 4,427,092 (New Position) | Filing History |
| 2021-11-10 4:50 pm Purchase | 2021-11-02 | 13G | Entrada Therapeutics, Inc. TRDA | BAKER BROS. ADVISORS LP | 4,704,419 15.100% | 4,704,419 (New Position) | Filing History |